×
News Home

Fate Therapeutics Inc (FATE) Stock: Do Analysts Think You Should Buy?

Thursday, December 30, 2021 11:47 AM | InvestorsObserver Analysts
Fate Therapeutics Inc (FATE) Stock: Do Analysts Think You Should Buy?

Wall Street is positive on Fate Therapeutics Inc (FATE). On average, analysts give the stock a Strong Buy rating. The average price target is $103.866, which means analysts expect the stock to rise by 69.30% over the next twelve months. That average ranking earns the stock an Analyst Rating of 63, which is better than 63% of stocks based on data compiled by InvestorsObserver.

Overall Score - 4.7
Wall Street analysts are rating FATE a Strong Buy today. Find out what this means to you and get the rest of the rankings on FATE!

Why are Analyst Ratings Important?

You can learn a lot about a company from looking at it’s financial statements and comparing them to other companies. Analysts who cover an industry in depth can add even more to your research though. They typically follow a particular sector or industry very closely. They also pay attention to and ask questions on earnings conference calls and other events where they might learn information that does show up in the numbers. InvestorsObserver takes the average rating from these analysts, and then percentile ranks those averages. This lets you compare stocks in a much more granular way than just seeing the typical five-tiered rating system used on most of Wall Street.

What's Happening With Fate Therapeutics Inc Stock Today?

Fate Therapeutics Inc (FATE) stock is trading at $61.35 as of 11:46 AM on Thursday, Dec 30, a rise of $2.13, or 3.59% from the previous closing price of $59.22. The stock has traded between $58.52 and $62.28 so far today. Volume today is light. So far 166,777 shares have traded compared to average volume of 1,318,128 shares. Click Here to get the full Stock Report for Fate Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App